Tempest Therapeutics, Inc. (TPST) Operating income 2016–2025
Tempest Therapeutics, Inc. (TPST) annual operating income history from SEC filings — each fiscal year as reported.
-$26.6MFY2025 · since FY2016: -$81.0M → -$26.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$26.6M | +36.8% |
| FY2024 | -$42.0M | -44.1% |
| FY2023 | -$29.2M | +15.8% |
| FY2022 | -$34.6M | -28.4% |
| FY2021 | -$27.0M | -39.8% |
| FY2020 | -$19.3M | +57.5% |
| FY2019 | -$45.4M | -68.9% |
| FY2018 | -$26.9M | +68.1% |
| FY2017 | -$84.3M | -4.1% |
| FY2016 | -$81.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TPST financial trends
TPST RevenueTPST Net incomeTPST Net marginTPST Gross profitTPST Gross marginTPST Operating marginTPST Operating cash flowTPST Free cash flowTPST Capital expendituresTPST Return on equityTPST Stock buybacksTPST Dividends paidTPST Total assetsTPST Total liabilitiesTPST Shareholders’ equityTPST overview →